Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Qing Xie, Ph.D.

Qing Xie, Ph.D., is a Director, Computational Biology, Deerfield Discovery and Development and joined the Firm in 2022. Prior to Deerfield, Dr. Xie spent 22 years at GlaxoSmithKline (GSK), most recently as Associate Director, Computational Biology. Dr. Xie holds a B.S. in Biochemistry from Anhui University, in China, an M.S. in Biochemistry from the Beijing Institute of Pharmaceutical Chemistry, in China, and a Ph.D. in Molecular Biology from the University of Delaware.

Kristin Burns-Huang, Ph.D.

Kristin Burns-Huang, Ph.D., is an Associate Director, Project Management, Deerfield Discovery and Development and joined the Firm in 2022. Prior to Deerfield, Dr. Burns-Huang spent 10 years at Weill Cornell Medicine as a Research Assistant Professor, Research Coordinator, and Lab Manager in the lab of Dr. Carl Nathan. Dr. Burns-Huang holds a B.A. in Chemistry from Franklin and Marshall College, and a Ph.D. in Biochemistry from Cornell University.

Marc Feiglin

Marc Feiglin is Head of Innovative Technologies, Deerfield Discovery and Development, and joined the Firm in 2022 to work on the “Lab of the Future” project. Prior to joining Deerfield, Mr. Feiglin was a Senior Director, External Innovation, Corporate Development & Strategy at Thermo Fisher Scientific. Before that, Mr. Feiglin spent five years at Merck KGaA in various roles, most recently as Senior Director Alliance Management & Partnerships, Electronic Materials. Mr. Feiglin holds a B.S. in Biology from University of Michigan, and an M.B.A. jointly awarded by New York University, London School of Economics and HEC Paris.

Huijun Wang, Ph.D.

Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals, where she worked for three years. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck for more than five years and a Senior Scientist at Pfizer for more than three years. Dr. Wang holds a B.Sc. in Chemistry and a B.A. in Economics from Peking University in China, and an M.Sc. in Chemical Informatics, an M.Sc. in Computer Science, and a Ph.D. in Informatics from Indiana University Bloomington.

Abdul Khan, Ph.D.

Abdul Khan, Ph.D., is a Director, Biologics, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Khan was a Director, Protein Engineering at Molecular Templates for a year. Before this, he was most recently Senior Associate Director, Protein and Cell Line Engineering for Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), where he worked for more than five years. Dr. Khan holds a B.S. in Chemistry, Zoology, and Botany, an M.S. in Zoology, a Master of Philosophy in Molecular Biology from Punjab University, Pakistan, and a Ph.D. in Natural Sciences from University of Vienna, Austria.

Ankita Shah, Ph.D.

Ankita Shah, Ph.D.,is a Principal Scientist, Drug Product Development, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Shah spent four years at Freund-Vector Corporation, most recently as Senior Process Development Scientist. Dr. Shah holds a Bachelor of Pharmacy from L.M. College of Pharmacy in India, and an M.S. and a Ph.D. in Pharmaceutical Sciences from St. John’s University.

Carla Gauss, Ph.D.

Carla Gauss, Ph.D., is a Senior Director, Medicinal Chemistry, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Gauss was a Senior Application Scientist, Medicinal Chemistry at Nanome. Before Nanome, she served as a Research Investigator at Cold Spring Harbor Laboratory, where she worked for 11 years. Before this, Dr. Gauss held various positions as a scientist at Progenics Pharmaceuticals, Cara Therapeutics, Memory Pharmaceuticals and Exelixis. Dr. Gauss holds a B.S. in Chemistry and a B.A. in Biology from University of Virginia and a Ph.D. in Organic Chemistry from University of California at Irvine.

Eric Schiffhauer, Ph.D.

Eric Schiffhauer, Ph.D., is an Associate Director, Academic Outreach, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Schiffhauer spent three years at Northwestern University, most recently as a Scientific Collaboration Director. Before Northwestern, he held positions at Adi Family Office and Johns Hopkins Technology Ventures. Dr. Schiffhauer holds a B.S. in Biology from George Mason University and a Ph.D. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

Carrie Wei, Ph.D.

Carrie Wei, Ph.D., is a Director, Drug Metabolism and Pharmacokinetics, Deerfield Discovery and Development, and joined the Firm in 2022.  Prior to Deerfield, Dr. Wei spent three years at Biogen as an Associate Director and Team Leader, Drug Metabolism and Pharmacokinetics.  Before Biogen, Dr. Wei was a Group Leader and Principal Scientist, Drug Metabolism and Pharmacokinetics at Vertex Pharmaceuticals for three years and held various other roles of increasing responsibilities at Bristol Myers Squibb and Pfizer.  Dr. Wei holds a B.S. in Biological Sciences from Wuhan University, an M.S. in Biological Sciences and Neuroscience from Purdue University, and a Ph.D. in Pharmacology from University of Pennsylvania.

Kevin Goncalves, Ph.D.

Kevin Goncalves, Ph.D., is a Director, Preclinical Pharmacology, Deerfield Discovery and Development, and joined the Firm in 2022.  Prior to Deerfield, Dr. Goncalves spent nearly six years at Magenta Therapeutics in roles of increasing seniority, most recently as Director, Translational Sciences.  He holds a B.S. in Biology from Fairfield University and a Ph.D. in Cellular and Molecular Physiology from Tufts University.